Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Articles

Impaired Endothelium-Dependent Vasodilation of Large Epicardial and Resistance Coronary Arteries in Patients With Essential Hypertension

Different Responses to Acetylcholine and Substance P

Kensuke Egashira, Satoshi Suzuki, Yoshitaka Hirooka, Hisashi Kai, Masaru Sugimachi, Tsutomu Imaizumi, Akira Takeshita
https://doi.org/10.1161/01.HYP.25.2.201
Hypertension. 1995;25:201-206
Originally published February 1, 1995
Kensuke Egashira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Suzuki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitaka Hirooka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hisashi Kai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Sugimachi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsutomu Imaizumi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Takeshita
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract Hypertensive patients have impaired endothelium-dependent coronary vasodilation evoked with acetylcholine. The aim of this study was to examine whether the impaired endothelium-dependent dilation of coronary arteries is related to a specific abnormality of the muscarinic receptor that mediates the effects of acetylcholine. Responses of the large epicardial and resistance coronary arteries were assessed in seven hypertensive patients (mean arterial pressure, 106±14 mm Hg) and seven control subjects (83±6 mm Hg, P<.01) during cardiac catheterization. To assess coronary endothelial function, we infused acetylcholine and substance P (endothelium-dependent agents that act on different receptors) and papaverine and nitrate (direct vascular smooth muscle dilators) into the left anterior descending coronary artery and determined coronary artery diameter by arteriography and coronary blood flow with an intracoronary Doppler catheter technique. In control subjects, 3 μg/min acetylcholine increased (P<.05) and 30 μg/min acetylcholine decreased (P<.05) arterial diameter, and in hypertensive patients, 1, 3, 10, and 30 μg/min acetylcholine decreased arterial diameter in a dose-dependent manner. Substance P at 3, 10, and 30 ng/min caused comparable increases in diameter in both groups. Increases in coronary blood flow with both acetylcholine and substance P were significantly (P<.01) blunted in hypertensive patients compared with control subjects. No significant differences were noted between the groups in the responses of large epicardial coronary artery diameter and coronary blood flow to papaverine and nitrate. Vasodilation of the large coronary artery with acetylcholine was impaired, but the response to substance P was preserved in hypertensive patients, indicating that diminished vasodilation of the large epicardial coronary artery in hypertensive patients may be related to a specific abnormality in the endothelial muscarinic receptor. Blunted coronary blood flow responses to both acetylcholine and substance P in hypertensive patients suggest that endothelial dysfunction in the resistance coronary artery in this condition is related to a more generalized endothelial abnormality but is not confined to the muscarinic receptor.

  • vasodilation
  • hypertension, essential
  • coronary circulation
  • acetylcholine
  • substance P
  • endothelium-derived relaxing factor

Essential hypertension is associated with many structural and functional abnormalities in the coronary arteries.1 2 3 Structural abnormalities include hypertrophy and hyperplasia of vascular smooth muscle and accumulation of collagen in the perivascular space, leading to a decrease in lumen size.1 2 3 Functional abnormalities include defective endothelium-mediated control of vascular tone.4 5 6

The vascular endothelium plays an important role in the control of vascular tone by releasing various endothelium-derived vasoactive substances.7 8 9 10 11 12 Recently, it was shown in humans that endothelium-dependent coronary and forearm vasodilation evoked with acetylcholine is defective in several pathophysiological conditions,13 14 15 16 17 including hypertension.4 5 6 18 19 20 More recently, Panza et al21 have reported that an inhibitory effect of NG-monomethyl-l-arginine (an inhibitor of endothelium-derived nitric oxide) on acetylcholine-induced forearm vasodilation is significantly less in hypertensive patients than control subjects, indicating that a decreased release of endothelium-derived nitric oxide evoked with acetylcholine is involved in the mechanism responsible for impaired endothelium-dependent forearm vasodilation in hypertensive patients. In these previous studies, however, endothelial function in hypertensive patients was assessed exclusively by examination of vasomotor responses to acetylcholine, which stimulates the release of nitric oxide through the endothelial muscarinic receptor.7 8 9 10 11 12

Substance P, another endothelium-dependent vasodilator, is know to act on an endothelial tachykinin receptor that is different from the muscarinic receptor.22 23 Recent studies24 25 suggest that large epicardial coronary artery segments that show an abnormal response to acetylcholine may have preserved vasodilator responses to substance P in patients with coronary atherosclerosis or vasospasm. The concomitant use of acetylcholine and substance P in a certain condition may help test the hypothesis of whether endothelial dysfunction is related to a specific abnormality of the endothelial muscarinic receptor. However, this hypothesis has not been tested in hypertensive patients. Investigation of this hypothesis in essential hypertension appears to be important because it could provide a more precise knowledge concerning the mechanisms responsible for impaired endothelium-dependent coronary vasodilation in this condition.

Therefore, the aim of this study was to determine whether impaired endothelium-dependent dilation of large epicardial and resistance coronary arteries is caused by a specific abnormality of the muscarinic receptor or by a more generalized abnormality of the endothelium. For this purpose, we assessed responses of the large epicardial coronary artery diameter and coronary blood flow to acetylcholine and substance P in patients with essential hypertension and normotensive control subjects.

Methods

Patients

The study was done in seven patients with essential arterial hypertension and seven normotensive control subjects undergoing diagnostic cardiac catheterization for evaluation of chest pain. All patients and subjects had atypical chest pain, normal exercise stress test results, angiographically normal coronary arteries, and normal left ventricular function. To assess the isolated effects of hypertension on coronary endothelial function, we excluded patients with diabetes mellitus, hypercholesterolemia (total cholesterol level >6.2 mmol/L [240 mg/dL] at the time of study), a history of myocardial infarction, variant angina, valvular heart diseases, or heart failure. Individuals with evidence of left ventricular hypertrophy as assessed by electrocardiogram and echocardiogram were also excluded. A history of hypertension was defined as a blood pressure elevation greater than 160/95 mm Hg requiring the use of antihypertensive drugs. No patients or subjects were on cholesterol-lowering drugs before study. Hypertensive patients were being treated with various antihypertensive drugs.

The research protocol of this study was approved by the institutional committee for clinical research. Written informed consent was obtained from each participant.

Quantitative Coronary Angiography

Coronary cineangiograms were recorded with a cineangiographic system (Siemens Inc). An appropriate view that allowed the best visualization of the left anterior descending coronary artery (the study artery) was selected.

We determined changes in the luminal diameter of the left anterior descending coronary artery, a segment 2 to 3 mm distal to the tip of the Doppler catheter, as described previously.15 16 17 The end-diastolic frame was selected on a cine projector. The images of interest were taken into a videodensitometric analyzer (Kontron Instruments) and digitized. The diameter of the segment of interest was measured for later analysis. A Judkins catheter was used to calibrate the arterial diameter in millimeters. Arterial diameter measurements were done blindly without knowledge of the clinical characteristics of the patients or subjects.

Measurement of Coronary Blood Flow Velocity and Estimation of Coronary Blood Flow

An 8F angioplasty-guiding catheter was introduced into the left main coronary artery through a femoral approach. A 3F Doppler flow-velocity catheter (model DC-201, Millar Instruments) was introduced into the left anterior descending coronary artery. The Doppler catheter then was connected to a DC-101 Velocimeter (Millar Instruments) to obtain mean and phasic velocity signals. Increases in coronary blood flow were estimated from the product of the mean coronary blood flow velocity and the cross-sectional area of the arterial segment at the tip of the Doppler catheter and were expressed as percent increases from baseline as described previously.15 16 17

Study Protocol

Cardiac catheterization was performed with patients and subjects in the fasting state after premedication with 5 mg oral diazepam. Control subjects were not receiving antianginal or antihypertensive drugs before the study. All hypertensive patients were receiving drugs such as nitrates, calcium channel blockers, β-blockers, and angiotensin-converting enzyme inhibitors. These drugs were discontinued 3 days before the study; during this period, patients were monitored for blood pressure elevation.

After completion of the diagnostic catheterization, the following interventions were performed: (1) a bolus injection of papaverine (10 mg/5 mL) through the guiding catheter; (2) infusion of saline (0.5 to 1.0 mL/min for 2 minutes) through the Doppler catheter; (3) infusions of acetylcholine (0.5 to 1.0 mL/min) at 1, 3, 10, and 30 μg/min (for 2 minutes at each dose) through the Doppler catheter; (4) infusions of substance P at 3, 10, and 30 ng/min through the Doppler catheter; and (5) bolus injection of 2 mg isosorbide dinitrate. After completion of the study with one drug, we waited for at least 5 minutes before beginning infusion of the next drug, by which time the coronary diameter and coronary blood flow velocity returned to baseline values. Coronary arteriography was performed before and 2 minutes after each drug. Mean and phasic coronary blood flow velocities, arterial pressure, heart rate, and standard 12-lead electrocardiograms were monitored continuously and recorded on a multichannel recorder (Nihon Kohden Polygraph System). Steady-state values were used for later analysis.

Statistical Analysis

Data are expressed as mean±SD or SEM. When serial changes in hemodynamic variables to the graded doses of drugs were compared, one-way ANOVA was used. When the responses were compared between study groups, two-way ANOVA for repeated measures followed by Bonferroni’s multiple comparison test was used. A value of P<.05 was considered statistically significant.

Clinical characteristics such as age, sex, arterial pressure, and serum cholesterol levels were compared between hypertensive patients and control subjects by Student’s t tests or χ2 tests. The effects of these clinical factors on coronary vasomotion in response to acetylcholine were examined by multiple linear regression analysis.

Results

Clinical Characteristics and Hemodynamic Data

The clinical characteristics of hypertensive patients and control subjects were comparable with regard to age, male sex, total serum cholesterol level, and history of cigarette smoking (Table⇓). Left ventricular diastolic and systolic dimensions and left ventricular posterior wall thickness as determined by echocardiogram did not differ between the two groups.

View this table:
  • View inline
  • View popup
Table 1.

Clinical Characteristics of Study Patients

Systolic, diastolic, and mean arterial pressures at the time of study were significantly higher in hypertensive patients than control subjects. Heart rate and left ventricular end-diastolic pressure were similar between the two groups. The diameter of the proximal segments of the left anterior descending coronary artery at baseline was similar in the two groups. Baseline mean arterial pressure and heart rate before drugs did not significantly change during the study in either hypertensive patients or control subjects (data not shown). Mean arterial pressure and heart rate were not significantly altered by intracoronary administration of either acetylcholine, substance P, papaverine, or nitrate, as described previously.15 16 17 24 25

Responses of the Large Epicardial Coronary Artery

Intracoronary infusion of saline did not change the diameter of the large epicardial coronary artery. In control subjects, acetylcholine at the low dose (3 μg/min) increased (P<.05 by one-way ANOVA and multiple comparison tests) and at the high dose (30 μg/min) decreased (P<.05) arterial diameter (Fig 1⇓). In hypertensive patients, acetylcholine significantly decreased (P<.01 by one-way ANOVA) arterial diameter in a dose-dependent manner. No significant vasodilation of the large epicardial coronary artery was noted in hypertensive patients. The vasoconstrictor responses of the large epicardial coronary artery to acetylcholine in hypertensive patients were significantly greater (P<.01 by two-way ANOVA and multiple comparison tests) than the responses in control subjects. The effects of clinical characteristics (Table⇑) on the vasoconstrictor response to 30 μg/min acetylcholine were assessed by multiple regression analysis; arterial pressure but not the other factors significantly (P<.01) correlated with the response to acetylcholine.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Line graphs show effects of acetylcholine (left) and substance P (right) on vasomotor responses of the large epicardial coronary artery in hypertensive patients (•) and control subjects (○). Percent changes in large epicardial coronary artery diameter in response to drugs are presented. **P<.01 vs control by two-way ANOVA and multiple comparison tests. Values are mean±SEM.

Substance P significantly increased (P<.01 by one-way ANOVA) arterial diameter in hypertensive patients and control subjects. The vasodilator responses of the large epicardial coronary artery to substance P were comparable between the two groups (Fig 1⇑).

The vasodilator responses to papaverine (4±3% and 4±4% in hypertensive patients and control subjects, respectively) and nitrate (15±2% and 11±1%) were comparable between the two groups.

Responses of Coronary Blood Flow

Intracoronary infusion of saline did not change coronary blood flow. A real-time tracing of coronary blood flow velocity during drug infusion in a control subject is presented in Fig 2⇓. Both acetylcholine and substance P increased coronary blood flow in a dose-dependent manner in hypertensive patients and control subjects. The increases in coronary blood flow evoked with acetylcholine were markedly less (P<.01 by two-way ANOVA) in hypertensive patients than control subjects (Fig 2⇓). The percent increases in coronary blood flow with acetylcholine at 1, 3, 10, and 30 μg/min were 13±9%, 37±17%, 67±16%, and 184±76%, respectively, in hypertensive patients and 49±17%, 179±42%, 289±36%, and 372±23%, respectively, in control subjects. Multiple regression analysis showed that there was a significant negative correlation between arterial pressure and the percent increase in coronary blood flow evoked with 30 μg/min acetylcholine.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Real-time tracings show electrocardiogram (ECG), arterial pressure (AoP), and coronary blood flow velocity (CBFV) during infusion of saline, papaverine, and acetylcholine.

The percent increases in coronary blood flow evoked with substance P were also significantly less (P<.01 by two-way ANOVA) in hypertensive patients than control subjects (Fig 3⇓). The percent increases in coronary blood flow evoked with substance P at 3, 10, and 30 ng/min were 10±5%, 20±6%, and 32±10% in hypertensive patients and 11±3%, 70±7%, and 143±28% in control subjects.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Line graphs show effects of acetylcholine (left) and substance P (right) on changes in coronary blood flow in hypertensive patients (•) and control subjects (○). Percent increases in coronary blood flow in response to acetylcholine and substance P are presented. **P<.01 vs control by two-way ANOVA and multiple comparison tests.

The percent increase in coronary blood flow in response to papaverine was similar between hypertensive patients (426±35%) and control subjects (394±34%, P=NS). The coronary blood flow response to nitrate was also similar between the groups (122±14% and 98±13%, hypertensive patients and control subjects, respectively, P=NS).

Discussion

We have made two new observations in the present study. First, vasodilator responses of the large epicardial coronary artery to substance P were preserved in hypertensive patients in whom acetylcholine produced significant vasoconstrictor responses, suggesting that endothelial dysfunction of the large epicardial coronary artery in hypertensive patients may be related to a specific abnormality of the muscarinic receptors that mediate the effect of acetylcholine. Second, the increases in coronary blood flow evoked with both acetylcholine and substance P were attenuated in hypertensive patients compared with control subjects. The latter finding suggests that defective endothelium-dependent vasodilation of the resistance coronary artery in hypertensive patients may not be related to a specific abnormality of the muscarinic receptor.

Endothelial Dysfunction in the Large Epicardial Coronary Artery in Hypertensive Patients

Our results that vasoconstrictor responses of the large epicardial coronary artery to acetylcholine in hypertensive patients were greater than those in control subjects are consistent with previous findings in animals and humans suggesting that hypertension is associated with diminished endothelium-dependent dilation of the large coronary artery.4 6 7 8 Previous studies have noted that atherosclerosis and various risk factors augment vasoconstrictor responses of angiographically normal-looking epicardial coronary arteries to acetylcholine.13 Our hypertensive patients had angiographically normal coronary arteries and no hypercholesterolemia or diabetes mellitus. Age, sex, and incidence of smoking were comparable between the two study groups. Furthermore, multiple linear regression analysis revealed that the levels of arterial pressure but not other clinical factors were significantly correlated with the responses of the large epicardial coronary artery and coronary blood flow to acetylcholine. Thus, as reported in previous studies,4 5 6 7 8 it is likely that augmented vasoconstrictor responses of the large epicardial coronary artery to acetylcholine were related to hypertension. However, we cannot exclude the possibility that the presence of angiographically undetected atherosclerosis was responsible for these findings.

It has been shown that acetylcholine and substance P dilate the large epicardial coronary artery by the release of endothelium-derived nitric oxide.26 27 28 29 However, acetylcholine and substance P act on different receptors to evoke the release of nitric oxide: muscarinic and tachykinin receptors, respectively.22 23 A new finding of the present study is that endothelium-dependent vasodilation of the large epicardial coronary artery evoked with substance P was preserved in hypertensive patients who had diminished endothelium-dependent vasodilation with acetylcholine. Endothelium-independent vasodilation with papaverine and nitrate was comparable in hypertensive patients and control subjects. These results suggest that diminished endothelium-dependent vasodilation of the large epicardial coronary artery with acetylcholine in hypertensive patients was related to a selective abnormality in the endothelial muscarinic receptor of the large epicardial coronary artery.

It has been shown that the increase in flow produces mechanical shear stress on the endothelial cell surface and thus causes endothelium-dependent vasodilation of large conduit vessels including the human epicardial coronary artery.30 31 Therefore, we do not exclude the possibility that diminished vasodilation of the large epicardial coronary artery in response to acetylcholine in hypertensive patients might have resulted from altered flow-induced endothelium-dependent vasodilation and not be related to an abnormality in the endothelial muscarinic receptor, since coronary blood flow could not be controlled in our patients. However, we consider it plausible that diminished endothelium-dependent vasodilation of the large epicardial coronary artery with acetylcholine in hypertensive patients may not totally be explained by attenuated flow-induced vasodilation. This hypothesis is based on the following findings. First, vasodilation of the large epicardial coronary artery with substance P in hypertensive patients was equivalent to that in control subjects, whereas the increases in coronary blood flow in response to substance P were markedly blunted in the hypertensive patients (Figs 1⇑ and 3⇑). Second, 1 μg/min acetylcholine, which did not significantly increase coronary blood flow in either group, produced a significant difference in the response of the large epicardial coronary artery between hypertensive patients and control subjects. Acetylcholine at high doses (10 to 30 μg/min), which markedly increased coronary blood flow, caused progressive vasoconstriction of the large epicardial coronary artery in both groups.

Endothelial Dysfunction in the Resistance Coronary Artery in Hypertensive Patients

It is reasonable to assume that the increases in coronary blood flow evoked with the drugs used in this study reflected vasodilation of the resistance coronary artery, because these drugs increased coronary blood flow without altering arterial pressure and heart rate. Although acetylcholine caused a modest vasoconstriction of the large epicardial coronary artery, we15 16 17 and other investigators32 have previously shown that this degree of vasoconstriction of the large epicardial coronary artery does not attenuate the coronary blood flow responses to vasodilator stimuli. Thus, it is unlikely that the acetylcholine-induced vasoconstriction of the large coronary artery might have limited the coronary blood flow responses to acetylcholine.

Previous studies have indicated that endothelium-dependent vasodilation of the resistance coronary artery evoked with acetylcholine is impaired in hypertensive patients,5 6 which agrees with the data presented in the present study. However, the coronary blood flow response to another endothelium-dependent vasodilator such as substance P has not been studied in hypertensive patients. We found in the present study that the coronary blood flow responses to both acetylcholine and substance P were attenuated in hypertensive patients, indicating that endothelium-dependent dilation of the resistance coronary artery in response to both drugs was impaired in our hypertensive patients. We also demonstrated that the endothelium-independent responses to papaverine and nitrate were similar between hypertensive patients and control subjects, indicating that altered endothelium-dependent responses in hypertensive patients did not result from a nonspecific abnormality in the response of vascular smooth muscle. These findings indicate that defective endothelium-dependent vasodilation of the resistance coronary artery in hypertensive patients is related to a more generalized abnormality of endothelial cells in response to diverse stimuli but not confined to a local endothelial abnormality at the muscarinic receptor level.

Recently, Panza et al,21 using a specific inhibitor of endothelium-derived nitric oxide (NG-monomethyl-l-arginine), have suggested that impaired endothelium-dependent forearm vasodilation in hypertensive patients is related to a decreased release of nitric oxide. However, we could not determine the degree to which endothelium-derived nitric oxide might be involved in the mechanisms responsible for impaired endothelium-dependent vasodilation of the resistance coronary artery in hypertensive patients because responses of the resistance coronary artery to acetylcholine and substance P were not assessed before and after an inhibitor of endothelium-derived nitric oxide. Therefore, we do not know whether endothelial dysfunction in the resistance coronary artery in hypertensive patients is related to reduced release of endothelium-derived nitric oxide or hyperpolarizing factor,33 inactivation of endothelium-derived relaxing factors,34 or augmented release of endothelium-derived constricting factors.35 Further studies are needed to determine the relative contributions of these possibilities in impaired endothelium-dependent coronary vasodilation in this condition.

Conclusion

The results of this study suggest that diminished endothelium-dependent dilation of the large epicardial coronary artery in hypertensive patients may be related to a selective abnormality in the muscarinic receptor of the endothelium and that blunted endothelium-dependent dilation of the resistance coronary artery in this condition may be related to a more generalized endothelial abnormality but not confined to the muscarinic receptor. These findings may contribute to our understanding of the pathophysiology of altered endothelial function of the coronary arteries in hypertensive patients.

Acknowledgments

This study was supported by grants-in-aid for scientific research (Nos. 05670617 and 05857085) from the Ministry of Education, Science and Culture, Tokyo, Japan; by a Japan Cardiovascular Research Foundation research grant, Osaka, Japan; and by a Japan Heart Foundation research grant, Tokyo, Japan.

  • Received September 6, 1994.
  • Revision received October 19, 1994.
  • Accepted October 19, 1994.

References

  1. ↵
    Harrison DG, Marcus ML, Dellsperger KC, Lamping KG, Tomanek RJ. Pathophysiology of myocardial perfusion in hypertension. Circulation. 1991;83(suppl III):III-14-III-18.
  2. ↵
    Bache RJ. Effects of hypertrophy on the coronary circulation. Prog Cardiovasc Dis. 1988;31:403-440.
    OpenUrl
  3. ↵
    Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993;88:993-1003.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Treasure CB, Manoukian SV, Klein JL, Vita JA, Nabel EG, Renwick GH, Selwyn AP, Alexander RW, Ganz P. Epicardial coronary artery responses to acetylcholine are impaired in hypertensive patients. Circ Res. 1992;71:776-781.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Treasure CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation. 1993;87:86-93.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Brush JE Jr, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol. 1992;19:809-815.
    OpenUrlPubMed
  7. ↵
    Bassenge E, Busse R. Endothelial modulation of coronary tone. Prog Cardiovasc Dis. 1988;30:349-380.
    OpenUrlCrossRefPubMed
  8. ↵
    Lüscher TF, Richard V, Tschudi M, Yang Z, Boulanger C. Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol. 1990;15:519-527.
    OpenUrlPubMed
  9. ↵
    Myers PR, Banit PF, Guerra R Jr, Harrison DG. Characteristics of canine resistance arteries: importance of endothelium. Am J Physiol. 1989;257:H603-H610.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Griffith TM, Edwards DH, Dadies RLI, Harrison TJ, Evans KT. EDRF coordinates the behaviour of vascular resistance vessels. Nature. 1987;329:442-445.
    OpenUrlCrossRefPubMed
  11. ↵
    Vallance P, Collier J, Moncada S. Effects of endothelium-dependent nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
    OpenUrlPubMed
  12. ↵
    Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res. 1990;66:1561-1575.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Zeiher AM, Drexler H, Wollschlyger H, Just H. Modulation of coronary vascular tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
  16. ↵
    Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urabe Y, Takeshita A. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 1993;88:77-81.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-1664.
    OpenUrlCrossRefPubMed
  18. ↵
    Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
    OpenUrlCrossRefPubMed
  19. ↵
    Linder L, Kiowski W, Buhler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762-1767.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Hirooka Y, Imaizumi T, Masaki H, Ando S, Harada S, Momohara M, Takeshita A. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension. 1992;20:175-180.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468-1474.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Saito R, Nonaka S, Konishi H, Takeo Y, Shimohigashi Y, Matsumoto H, Ohno M, Kamiya H. Pharmacological properties of the tachykinin receptor subtype in the endothelial cells and vasodilation. Ann N Y Acad Sci. 1991;632:457-459.
    OpenUrlCrossRefPubMed
  23. ↵
    Furchgott RF. Role of endothelium in response of vascular smooth muscle. Circ Res. 1983;53:557-573.
    OpenUrlFREE Full Text
  24. ↵
    Egashira K, Inou T, Yamada A, Hirooka Y, Takeshita A. Preserved endothelium-dependent vasodilation at the vasospastic site in patients with variant angina. J Clin Invest. 1992;89:1047-1052.
  25. ↵
    Egashira K, Inou T, Yamada A, Hirooka Y, Urabe Y, Nagasawa K, Takeshita A. Heterogenous effects of the endothelium-dependent vasodilators acetylcholine and substance P on the coronary circulation of patients with angiographically normal coronary arteries. Coron Artery Dis. 1992;3:945-952.
    OpenUrl
  26. ↵
    Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest. 1987;79: 170-174.
  27. ↵
    Toda N, Okamura T. Endothelium-dependent and independent responses to vasoactive substances of isolated human coronary arteries. Am J Physiol. 1989;257:H988-H995.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Chester AH, O’Neil GS, Moncada S, Tadjkarimi S, Yacoub M. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet. 1990;336:897-900.
    OpenUrlCrossRefPubMed
  29. ↵
    Förstermann U, Mügge A, Alheid U, Haverich A, Frölich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res. 1988;62:185-190.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Drexler H, Zeiher AM, Woolesshaeger H, Meinertz T, Just H, Bonzel T. Flow dependent coronary artery dilation in humans. Circulation. 1989;80:466-474.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Cox DA, Vita JA, Treasure CB, Fish D, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-465.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Tatineni S, Kern MJ, Aguirre F. The effect of ergonovine on coronary vasodilatory reserve in patients with angiographically normal coronary arteries. Am Heart J. 1992;123:617-620.
    OpenUrlCrossRefPubMed
  33. ↵
    Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T, Tanaka Y, Fujishima M. Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneous hypertensive rats. Circ Res. 1992;70:660-669.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Auch-Schwelk W, Katusic ZS, Vanhoutte PM. Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta. Hypertension. 1992;19:442-445.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    Lüscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of spontaneously hypertensive rats. Hypertension. 1990;8:344-348.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
February 1995, Volume 25, Issue 2
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Impaired Endothelium-Dependent Vasodilation of Large Epicardial and Resistance Coronary Arteries in Patients With Essential Hypertension
    Kensuke Egashira, Satoshi Suzuki, Yoshitaka Hirooka, Hisashi Kai, Masaru Sugimachi, Tsutomu Imaizumi and Akira Takeshita
    Hypertension. 1995;25:201-206, originally published February 1, 1995
    https://doi.org/10.1161/01.HYP.25.2.201

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Impaired Endothelium-Dependent Vasodilation of Large Epicardial and Resistance Coronary Arteries in Patients With Essential Hypertension
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Impaired Endothelium-Dependent Vasodilation of Large Epicardial and Resistance Coronary Arteries in Patients With Essential Hypertension
    Kensuke Egashira, Satoshi Suzuki, Yoshitaka Hirooka, Hisashi Kai, Masaru Sugimachi, Tsutomu Imaizumi and Akira Takeshita
    Hypertension. 1995;25:201-206, originally published February 1, 1995
    https://doi.org/10.1161/01.HYP.25.2.201
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured